Phase 1/2Data readout

Amtagvi/Lifileucel (LN-144) (TIL Therapy)

Cancer, Merkel Cell Carcinoma

IOVAIovance Biotherapeutics

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: Amtagvi/Lifileucel (LN-144) (TIL Therapy)
Development stage: Phase 1/2
Event type: Data readout
Indication: Cancer, Merkel Cell Carcinoma

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for Amtagvi/Lifileucel (LN-144) (TIL Therapy) in Cancer, Merkel Cell Carcinoma. The expected timing is based on the latest available company guidance and may change.

Development notes

08/06/26:- Lifileucel IST treated MCC patients; initial data expected H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Phase 1/2Data readout

Amtagvi/Lifileucel (LN-144) (TIL Therapy)

Cancer, Merkel Cell Carcinoma

IOVAIovance Biotherapeutics

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: Amtagvi/Lifileucel (LN-144) (TIL Therapy)
Development stage: Phase 1/2
Event type: Data readout
Indication: Cancer, Merkel Cell Carcinoma

Research summary

What is being tracked?

Development notes

08/06/26:- Lifileucel IST treated MCC patients; initial data expected H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Amtagvi/Lifileucel (LN-144) (TIL Therapy)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Iovance TIL (LN-145)